Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

Citigroup Downgrades Mirati Therapeutics to Neutral, Raises Price Target to $59

Author: Benzinga Newsdesk | December 20, 2023 06:54am

Citigroup analyst Yigal Nochomovitz downgrades Mirati Therapeutics (NASDAQ:MRTX) from Buy to Neutral and raises the price target from $48 to $59.

Posted In: MRTX